Skip to main content

Advertisement

Table 2 Subgroup analysis according to serum ferritin level (n = 80)

From: Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer patients treated with Korean medicine: a retrospective cohort study

Variables Values Ferritin (ng/mL) P-value
Lowa Highb
n = 45 n = 35
Age (years) < 65 / ≥65 31/14 19/16 0.181
Gender Female / Male 15/30 12/23 0.930
ECOG-PS 0–1 / 2 42/3 24/11 0.004
BMI (kg/m2) < 23 / ≥23 23/22 21/14 0.430
Tumor Type HCC / BTC or cHCC-CC 22/23 11/24 0.116
Previous anticancer therapy No / Yes 11/34 14/21 0.136
Hb (g/dL) Lowc / Highd 28/17 22/13 0.950
Total bilirubin (mg/dL) ≤1.2 / > 1.2 37/8 27/8 0.570
AST (IU/L) < 40 / ≥40 24/21 13/22 0.150
ALT (IU/L) < 40 / ≥40 27/18 19/16 0.610
γ-GT (IU/L) ≤66 / > 66 22/23 3/32 < 0.001
PT INR ≤1.16 / > 1.16 32/13 25/10 0.980
Albumin (g/dL) < 3.5 / ≥3.5 7/38 6/29 0.850
WBC (×103/μL) < 10.0 / ≥10.0 43/2 27/8 0.013
CRP (mg/L) < 10.0 / ≥10.0 31/14 9/26 < 0.001
  1. ECOG-PS Eastern cooperative oncology group performance status, BMI body mass index, Hb hemoglobin, AST aspartate aminotransferase, ALT alanine aminotransferase, γ-GT gamma-glutamyl transpeptidase, PT INR prothrombin time international normalized ratio, WBC white blood cell, CRP c-reactive protein, HCC hepatocellular carcinoma, BTC biliary tract cancers, cHCC-CC combined hepatocellular-cholangiocarcinoma
  2. a female≤150 male≤200, b female> 150 male> 200, c female < 12.0 male < 13.0, d female ≥12.0 male ≥13.0